Edwards Lifesciences
922 hedge funds and large institutions have $33.6B invested in Edwards Lifesciences in 2019 Q1 according to their latest regulatory filings, with 121 funds opening new positions, 299 increasing their positions, 335 reducing their positions, and 65 closing their positions.
86% more first-time investments, than exits
New positions opened: 121 | Existing positions closed: 65
25% more capital invested
Capital invested by funds: $26.8B → $33.6B (+$6.75B)
9% more funds holding in top 10
Funds holding in top 10: 23 → 25 (+2)
5% more funds holding
Funds holding: 874 → 922 (+48)
9% more call options, than puts
Call options by funds: $335M | Put options by funds: $308M
0.84% less ownership
Funds ownership: 254.16% → 253.32% (-0.84%)
11% less repeat investments, than reductions
Existing positions increased: 299 | Existing positions reduced: 335
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$283M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$140M |
| 3 |
BlackRock
New York
|
+$134M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$103M |
| 5 |
FAM
Fred Alger Management
New York
|
+$73.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$511M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$214M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
-$96.9M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$68.9M |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
-$67.3M |
EW Hedge Fund Activity: Q1 2019 in Review
922 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q1 2019, worth a combined $33.6B — up 25% from $26.8B a quarter earlier.
Buyers outnumbered sellers: 121 funds opened new EW positions and 65 closed out — a net gain of 56 holders — while 299 added to existing stakes and 335 trimmed.
The largest buyer was Jennison Associates, adding an estimated $283M. The largest seller was Vanguard Group, cutting an estimated $511M.
- 922 institutional investors held Edwards Lifesciences (EW) as of Q1 2019, up from 874 in Q4 2018.
- Funds reported $33.6B of Edwards Lifesciences stock for Q1 2019, up 25% quarter-over-quarter.
- 121 funds opened new Edwards Lifesciences positions in Q1 2019 and 65 closed out, a net change of +56 holders.
- The largest Edwards Lifesciences buyer in Q1 2019 was Jennison Associates, an estimated $283M added.
- The largest Edwards Lifesciences seller in Q1 2019 was Vanguard Group, an estimated $511M sold.
Based on aggregated 13F filings for Q1 2019.